The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination
Open accessAbstract
Purpose: Because the combination of multiple modalities for cancer treatment is more likely to generate more potent therapeutic effects for the control of cancer, we have explored the combination of chemotherapy using cisplatin, which is routinely used in chemotherapy for advanced cervical cancer, with immunotherapy using DNA vaccines encoding calreticulin (CRT) linked to human papillomavirus type 16 E7 antigen (CRT/E7) in a preclinical model. Experimental Design: We characterized the combination of cisplatin with CRT/E7 DNA vaccine using different regimen for its potential ability to generate E7-specific CD8+ T-cell immune responses as well as antitumor effects against E7-expressing tumors. Results: Our results indicate that treatment of tumor-bearing mice with chemoimmunotherapy combining cisplatin followed by CRT/E7 DNA generated the highest E7-specific CD8+ T-cell immune response and produced the greatest antitumor effects and long-term survival as well as significant levels of E7-specific tumor-infiltrating lymphocytes compared with all the other treatment regimens. Furthermore, we found that treatment with cisplatin leads to the cell-mediated lysis of E7-expressing tumor cells in vitro and increased number of E7-specific CD8+ T-cell precursors in tumor-bearing mice. In addition, we observed that E7-specific CD8+ T cells migrate to and proliferate in the location of TC-1 tumors in mice treated with cisplatin. Conclusions: Thus, our data suggest that chemoimmunotherapy using cisplatin followed by CRT/E7 DNA vaccine is an effective treatment against E7-expressing tumors and may potentially be translated into the clinical arena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Cited by
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 395
Self-citationPatente, T. A., Pinho, M. P., Oliveira, A. A., Evangelista, G. C. M., Bergami-Santos, P. C., & Barbuto, J. A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03176 · Cited by 392
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
Metadata
- Authors
- Tseng, C.-W., Hung, C.-F., Alvarez, R. D., Trimble, C., Huh, W. K., Kim, D., Chuang, C.-M., Lin, C.-T., Tsai, Y.-C., He, L., Monie, A., & Wu, T.-C.
- Venue
- Clinical Cancer Research
- Published
- 2008-05-15
- Volume
- 14
- Issue
- 10
- Pages
- 3185-3192
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2136572822
- Cited by
- 158
- References
- 1
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-0037
- The paper
- Tseng, C.-W., Hung, C.-F., Alvarez, R. D., Trimble, C., Huh, W. K., Kim, D., Chuang, C.-M., Lin, C.-T., Tsai, Y.-C., He, L., Monie, A., & Wu, T.-C. (2008). Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-0037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.